

## **Four universities collaborate to introduce a European Masters Programme in Medicines Regulatory Affairs**

The Universities of Copenhagen, Basel, Hertfordshire and King's College, London, have signed a Memorandum of Understanding whereby they will work together in harmonising programmes to produce a common Masters programme in Medicines Regulatory Affairs. They will implement a common syllabus that has been developed by a team representing the universities, pharmaceutical companies and professional societies in the PharmaTrain project of the Innovative Medicines Initiative (IMI), as well as regulatory authorities across Europe.

Michel Goldman Executive Director of IMI welcomed the announcement by saying that “this Masters programme will help both new and existing drug development professionals to ensure their work is in line with the latest developments in regulatory affairs”.

Initially the programme is being offered by the University of Copenhagen in collaboration with Medicademy and the University of Hertfordshire in collaboration with The Organisation for Professionals in Regulatory Affairs (TOPRA). The University of Basel with DIA Europe Middle East and Africa; and King's College, London, are offering modules for the new programme.



Further information:

**Universities:**

King's College London: [www.kcl.ac.uk](http://www.kcl.ac.uk);

University of Basel, European Center of Pharmaceutical Medicine: [www.ecpm.ch](http://www.ecpm.ch);

University of Copenhagen: [www.ku.dk](http://www.ku.dk);

University of Hertfordshire: [www.herts.ac.uk](http://www.herts.ac.uk); [Innovative Medicines Initiative](#);

**Course providers:**

Medicademy: [www.medicademy.net](http://www.medicademy.net)

Topra: [www.topra.org](http://www.topra.org)

DIA EMEA: [www.diaeuropa.org](http://www.diaeuropa.org)

**EU:**

Innovative Medicines Initiative: [www.imi.europa.eu](http://www.imi.europa.eu)

IMI PharmaTrain: [www.pharmatrain.eu](http://www.pharmatrain.eu)

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115013], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

